WellPoint says hepatitis C drugs Q1 cost was $50 mln

April 30 Wed Apr 30, 2014 9:18am EDT

April 30 (Reuters) - WellPoint Inc said on Wednesday during a conference call that it had spent $50 million on hepatitis C drugs during the first quarter.

That was the total amount the company spent in 2013 on treatments, it said. Gilead Sciences introduced Sovaldi this year, and with its $84,000 price tag and high cure rates, it has been closely watched by insurers tracking expenses.

WellPoint added $100 million in additional hepatitis C drug costs to its 2014 outlook and said it continued to watch its use closely. (Reporting by Caroline Humer; Editing by Lisa Von Ahn)

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article